ERYTECH Pharma Competitors

ERYTECH Pharma (NASDAQ:ERYP) and Vaxart (NASDAQ:VXRT) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, analyst recommendations and risk.

Profitability

This table compares ERYTECH Pharma and Vaxart's net margins, return on equity and return on assets.

Earnings and Valuation

This table compares ERYTECH Pharma and Vaxart's gross revenue, earnings per share (EPS) and valuation.

Vaxart has higher revenue and earnings than ERYTECH Pharma. Vaxart is trading at a lower price-to-earnings ratio than ERYTECH Pharma, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

ERYTECH Pharma has a beta of 2.73, suggesting that its share price is 173% more volatile than the S&P 500. Comparatively, Vaxart has a beta of -0.11, suggesting that its share price is 111% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for ERYTECH Pharma and Vaxart, as reported by MarketBeat.

Vaxart has a consensus target price of $15.00, indicating a potential upside of 153.38%. Given Vaxart's higher possible upside, analysts clearly believe Vaxart is more favorable than ERYTECH Pharma.

Insider and Institutional Ownership

6.5% of ERYTECH Pharma shares are owned by institutional investors. Comparatively, 17.9% of Vaxart shares are owned by institutional investors. 7.3% of Vaxart shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Vaxart beats ERYTECH Pharma on 7 of the 12 factors compared between the two stocks.

Orchard Therapeutics (NASDAQ:ORTX) and ERYTECH Pharma (NASDAQ:ERYP) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, profitability, earnings, dividends, analyst recommendations and institutional ownership.

Risk & Volatility

Orchard Therapeutics has a beta of 1.31, meaning that its stock price is 31% more volatile than the S&P 500. Comparatively, ERYTECH Pharma has a beta of 2.73, meaning that its stock price is 173% more volatile than the S&P 500.

Institutional and Insider Ownership

66.6% of Orchard Therapeutics shares are owned by institutional investors. Comparatively, 6.5% of ERYTECH Pharma shares are owned by institutional investors. 4.2% of Orchard Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Orchard Therapeutics and ERYTECH Pharma's revenue, earnings per share and valuation.

ERYTECH Pharma has lower revenue, but higher earnings than Orchard Therapeutics. Orchard Therapeutics is trading at a lower price-to-earnings ratio than ERYTECH Pharma, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Orchard Therapeutics and ERYTECH Pharma, as reported by MarketBeat.com.

Orchard Therapeutics presently has a consensus target price of $14.75, indicating a potential upside of 115.01%. Given Orchard Therapeutics' higher possible upside, analysts plainly believe Orchard Therapeutics is more favorable than ERYTECH Pharma.

Profitability

This table compares Orchard Therapeutics and ERYTECH Pharma's net margins, return on equity and return on assets.

Summary

Orchard Therapeutics beats ERYTECH Pharma on 6 of the 11 factors compared between the two stocks.

ERYTECH Pharma (NASDAQ:ERYP) and Athira Pharma (NASDAQ:ATHA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, institutional ownership and valuation.

Institutional & Insider Ownership

6.5% of ERYTECH Pharma shares are held by institutional investors. Comparatively, 66.7% of Athira Pharma shares are held by institutional investors. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent ratings for ERYTECH Pharma and Athira Pharma, as provided by MarketBeat.com.

Athira Pharma has a consensus target price of $42.50, suggesting a potential upside of 120.32%. Given Athira Pharma's higher probable upside, analysts clearly believe Athira Pharma is more favorable than ERYTECH Pharma.

Valuation and Earnings

This table compares ERYTECH Pharma and Athira Pharma's top-line revenue, earnings per share (EPS) and valuation.

Profitability

This table compares ERYTECH Pharma and Athira Pharma's net margins, return on equity and return on assets.

Summary

Athira Pharma beats ERYTECH Pharma on 4 of the 4 factors compared between the two stocks.

Tarsus Pharmaceuticals (NASDAQ:TARS) and ERYTECH Pharma (NASDAQ:ERYP) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, dividends, risk, earnings, analyst recommendations, valuation and profitability.

Analyst Ratings

This is a breakdown of recent recommendations for Tarsus Pharmaceuticals and ERYTECH Pharma, as reported by MarketBeat.com.

Tarsus Pharmaceuticals currently has a consensus target price of $37.25, indicating a potential upside of 21.69%. Given Tarsus Pharmaceuticals' higher possible upside, equities analysts clearly believe Tarsus Pharmaceuticals is more favorable than ERYTECH Pharma.

Valuation and Earnings

This table compares Tarsus Pharmaceuticals and ERYTECH Pharma's gross revenue, earnings per share and valuation.

Profitability

This table compares Tarsus Pharmaceuticals and ERYTECH Pharma's net margins, return on equity and return on assets.

Institutional and Insider Ownership

6.5% of ERYTECH Pharma shares are owned by institutional investors. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Tarsus Pharmaceuticals beats ERYTECH Pharma on 3 of the 4 factors compared between the two stocks.

Agenus (NASDAQ:AGEN) and ERYTECH Pharma (NASDAQ:ERYP) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, risk, profitability, earnings and institutional ownership.

Earnings & Valuation

This table compares Agenus and ERYTECH Pharma's top-line revenue, earnings per share and valuation.

ERYTECH Pharma has lower revenue, but higher earnings than Agenus. Agenus is trading at a lower price-to-earnings ratio than ERYTECH Pharma, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Agenus has a beta of 1.86, suggesting that its stock price is 86% more volatile than the S&P 500. Comparatively, ERYTECH Pharma has a beta of 2.73, suggesting that its stock price is 173% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Agenus and ERYTECH Pharma, as reported by MarketBeat.com.

Agenus currently has a consensus price target of $8.00, indicating a potential upside of 153.16%. Given Agenus' higher probable upside, research analysts plainly believe Agenus is more favorable than ERYTECH Pharma.

Profitability

This table compares Agenus and ERYTECH Pharma's net margins, return on equity and return on assets.

Insider and Institutional Ownership

53.4% of Agenus shares are owned by institutional investors. Comparatively, 6.5% of ERYTECH Pharma shares are owned by institutional investors. 4.7% of Agenus shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Agenus beats ERYTECH Pharma on 6 of the 11 factors compared between the two stocks.

ERYTECH Pharma (NASDAQ:ERYP) and Precision BioSciences (NASDAQ:DTIL) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, institutional ownership, profitability, dividends, analyst recommendations and valuation.

Profitability

This table compares ERYTECH Pharma and Precision BioSciences' net margins, return on equity and return on assets.

Valuation and Earnings

This table compares ERYTECH Pharma and Precision BioSciences' gross revenue, earnings per share and valuation.

ERYTECH Pharma has higher earnings, but lower revenue than Precision BioSciences. Precision BioSciences is trading at a lower price-to-earnings ratio than ERYTECH Pharma, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

6.5% of ERYTECH Pharma shares are held by institutional investors. Comparatively, 48.6% of Precision BioSciences shares are held by institutional investors. 14.3% of Precision BioSciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent ratings and target prices for ERYTECH Pharma and Precision BioSciences, as provided by MarketBeat.

Precision BioSciences has a consensus target price of $20.00, suggesting a potential upside of 81.49%. Given Precision BioSciences' higher possible upside, analysts clearly believe Precision BioSciences is more favorable than ERYTECH Pharma.

Volatility and Risk

ERYTECH Pharma has a beta of 2.73, suggesting that its share price is 173% more volatile than the S&P 500. Comparatively, Precision BioSciences has a beta of 2.08, suggesting that its share price is 108% more volatile than the S&P 500.